Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

This is the latest version of the MitraClip, the G4, which allows each side of the clip to be opened and closed independently to offer more flexibility when capturing the valve leaflets. The device is being used in the REPAIR MR clinical trial.

News | Heart Valve Technology

New Study Looks at MitraClip use in Moderate Surgical Risk Patients

January 13, 2020 — The U.S. Food and Drug Administration (FDA) has approved clinical trial that will compare the ...

January 13, 2020

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

News | Cath Lab | Dave Fornell, Editor

EXCEL Trial Authors Say European Surgery Society Claims of Bad Science Are Groundless

January 2, 2020 — In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdre ...

January 02, 2020

Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)

News | Cardiovascular Clinical Studies

Top Cardiology News in 2019 From the European Society of Cardiology (ESC)

Environmental and lifestyle issues were popular this year, with pick up from both European Society of Cardiology (ESC) j ...

December 23, 2019

Vascepa pill contains a concentrated form of fish oil, icosapent ethyl, indication for prevention. The U.S. Food and Drug Administration (FDA) Dec. 13, 2019, approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive therapy to reduce the risk of cardiovascular events in adults with elevated triglyceride levels.

Feature | Pharmaceuticals | Dave Fornell, Editor

FDA Expands Vascepa to Reduce Cardiovascular Events in Elevated Triglyceride Patients

December 16, 2019 — The U.S. Food and Drug Administration (FDA), on Dec. 13, approved the use of Vascepa (icosapent ...

December 16, 2019

A key slide from the TRILUMINATE study one-year results showing the improvement in tricuspid regurgitation from basement with treatment using the transcatheter TriClip device.

News | Heart Valve Technology | Dave Fornell, Editor

TriClip Device For Tricuspid Regurgitation Effective at One Year in TRILUMINATE Study

November 26, 2019 — The preliminary one-year results of the TRILUMINATE Pivotal Study for Abbott's TriClip device, a ...

November 26, 2019

News | Cardiovascular Clinical Studies

Virtual Study to Track Statin-Related Adverse Events Being Undertaken by University of Connecticut and Hartford Healthcare

November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have ...

November 26, 2019

News | AHA

Weekend Sudden Cardiac Arrests are More Deadly

November 21, 2019 — People who experience cardiac arrests over the weekend are less likely to survive long enough to be ...

November 21, 2019

The Cordella Pulmonary Artery Pressure Sensor System for Heart failure. #AHA19 #AHA

News | Heart Failure

Positive Results for SIRONA First-in-Human Trial of the Cordella PA Pressure Sensor System

November 21, 2019 — Endotronix, a digital health and medical technology company dedicated to advancing the treatment of ...

November 21, 2019

John J. V. McMurray presenting the DAPA-HF Trial at AHA 2019. It was part of the late-breaking presentations in the "Outside the Box: New Approaches to CVD Risk Reduction" session.

Blog | Heart Failure

Key Heart Failure Takeaways at AHA 2019

It’s an exciting time in the heart failure (HF) world right now with the emergence of new therapies, including ...

November 21, 2019

Heart failure VICTORIA TrIal a success. Dave Fornell

News | Heart Failure

Investigational Drug Vericiguat Reduced the Risk of Heart Failure Hospitalization in VICTORIA Trial

November 21, 2019 — Merck announced the results from the Phase 3 VICTORIA Study evaluating the efficacy and safety of ...

November 21, 2019

News | AHA

Heart Disease and Cancer Risk May be Linked

November 20, 2019 — Heart attack survivors may have an increased risk of developing cancer compared to people without ...

November 20, 2019

News | AHA

Too Much Ultra Processed Food Linked to Lower Heart Health

November 20, 2019 — Ultra-processed foods, which account for more than half of an average American’s daily calories, are ...

November 20, 2019

In the ISCHEMIA study, patients were randomized into one of two groups: a conservative strategy or an invasive strategy. Illustration by NYU Langone staff

Feature | AHA

ISCHEMIA Trial Results Find Interventions for Stable Heart Disease No better Than Drug Therapy

November 19, 2019 — After 12 years of collecting data, the results of the landmark ISCHEMIA (International Study of ...

November 19, 2019

Feature | AHA | Dave Fornell, Editor

American Heart Association 2019 Late-breaking Trials

November 19, 2019 — Here is a list of the key late-breaking clinical study presentations and links to the results at the ...

November 19, 2019

Results from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study shows that an investigational set of algorithms in the Medtronic Micra Transcatheter Pacing System (TPS) significantly improves synchrony and cardiac function in patients with atrioventricular (AV) block. This is an impaired electrical conduction between the chambers of the heart.

News | Pacemakers

New Algorithms in Medtronic Micra Pacemaker May Improve Synchrony and Cardiac Function in AV Block

(February 2020 update — the results of this trial led to the FDA clearnace of the Micra AV device in January 2020 - FDA ...

November 15, 2019